Cherylene is responsible for leading ElevateBio’s research groups for viral vector, gene editing and protein engineering technologies. She has twenty years of large and small biotech industry experience in the viral vector and cellular engineering fields.
Prior to ElevateBio, Cherylene was Associate Vice President of Molecular Biology at AgenTus Therapeutics, where she helped develop AgenTus’ CAR and TCR cell therapeutics, including their proprietary NY-ESO TCR. Earlier in her career, Cherylene spent over a decade at Amgen leading their viral vector and cell line engineering core, followed by a move to Bristol-Myers Squibb where she enabled BMS to form a high-value gene therapy collaboration to treat cardiovascular disease. She started her career in biotech developing lentiviral vectors for gene therapy at Mitch Finer’s early company, Cell Genesys.
Education & Accomplishments
Cherylene holds a Ph.D. in biochemistry and molecular biology from the University of Medicine and Dentistry of NJ and a B.A. in Chemistry from Rutgers University. She did her postdoctoral training at Stanford University.
Interested in working with people like Cherylene? We’re looking for pioneers and innovative thinkers committed to developing the next-generation of cell and gene therapies. Review our open roles and find your future.